NEW YORK (GenomeWeb) – Genomeon and Cloud Pharmaceuticals have signed an agreement to mine next-generation sequencing data to aid in drug development.
Under the terms of the agreement, Cloud Pharmaceuticals will be able to use Genomeon's microsatellite technology to find novel drug targets and companion biomarkers in NGS data.
Floyd, Virginia-based Genomeon analyzes short tandem repeat sequences, called microsatellites, which could serve as drug targets or biomarkers for diagnostic purposes.